Domain Therapeutics to present three posters at AACR 2023 annual meeting

Research findings highlight Domain Therapeutics’ precision research and therapeutic potential of novel GPCR targets, PAR2 and CCR8, to unlock new cancer treatment possibilities

Strasbourg, France – Montreal, Canada, April 6th, 2023 – Domain Therapeutics (“Domain” or “the Company”), a clinical-stage biopharmaceutical company developing innovative drug candidates focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology, today announces three posters the Company will be presenting at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023 in Orlando, Florida.

Based on clinical findings, including results of a large-scale meta-analysis, Protease-activated receptor 2 (PAR2) was identified as significantly associated with resistance to immune checkpoint blockade in cancer patients. With PAR2 representing a promising therapeutic target in oncology and immuno-oncology, Domain has developed a novel series of potent and selective PAR2 inhibitors which have demonstrated unique properties versus competitors.

The Company is also presenting further findings from its CCR8 depleting-antibody program, a promising target from which to derive novel immunotherapies. Based on the transcriptional analysis of tumor infiltrating immune cells, the G-protein coupled receptor CCR8 was found to be expressed on murine and human Tumor-infiltrating Tregs (TITR), a sub-family of immuno-suppressive cells which play a critical role in cancer, but not on proinflammatory effector T cells. Following a comprehensive in vitro benchmarking monoclonal antibody analysis, Domain identified key differentiating points of its candidates versus competitors.

Dr. Stephan Schann, VP Research at Domain Therapeutics, commented: “These new findings show the precise focus with which Domain is identifying promising new targets involved in immunosuppression, such as PAR2 and CCR8 receptors, which could lead to the development of more powerful therapeutic strategies. We are continuing to advance our leading GPCR precision research to identify first-in-class and best-in-class candidates in our efforts to unlock new possibilities in cancer and significantly improve patient outcomes.”

Details of Domain’s AACR abstracts which will be shown at the Orange County Convention Center, Orlando, Florida are provided below. All abstracts will be published in the online Proceedings of the AACR.

Title: Depleting hCCR8 mAb Therapy #1: Characterization of a broad collection of anti-hCCR8 mAbs

Abstract number: 2946 / 24
Poster session title: Therapeutic Antibodies 2
Location: Poster Section 23
Date and time: 17 April 2023 1:30 PM – 5:00 PM

Title: Depleting hCCR8 mAb Therapy #2: Selection of candidates for the development of innovative depleting anti-CCR8 therapeutic antibodies to control the immunosuppressive tumor microenvironment

Abstract number: 2945 / 23
Poster session title: Therapeutic Antibodies 2
Location: Poster Section 23
Date and time: 17 April 2023 1:30 PM – 5:00 PM

Title: Novel biased PAR2 inhibitors with best-in-class properties reduce resistance to both chemotherapy and immunotherapy in oncology models

Abstract number: 4961 / 7
Poster session title: Novel Targets and Pathways
Location: Poster Section 16
Date and time: 18 April 2023 1:30 PM – 5:00 PM

– ENDS –

For more information, please contact:

Consilium Strategic Communications

Amber Fennell,  Namrata Taak, Andrew Stern
Tel: +44 (0)20 3709 5813

NewCap (for French media)

Annie-Florence Loyer
Tel: +33 (0)

About Domain Therapeutics

Domain Therapeutics, a clinical-stage biopharmaceutical company operating in France and Canada, focuses on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Backed by decades of research and validated by multiple pharma partnerships, the Company ensures rigorous GPCR target identification and selection as well as thorough analysis of tumor complexity and mechanismes to deliver the next generation of immunotherapies.

Domain’s clinical-stage programs include the A2aR/A2b receptor antagonist, identified during a research collaboration with Merck KGaA, and DT-9081, its fully owned EP4 receptor antagonist. The Company is also successfully progressing an anti-CCR8 asset alongside a rich, optimized pipeline of first-in-class GPCR targets selected through Domain’s drug discovery platform.

The Company raised €39m ($42m) in early 2022 to develop high-value drug candidates to address GPCR-mediated immunosuppression in immuno-oncology. Domain is backed by a syndicate of leading international venture capital funds from Europe, Asia and North America.

Download the pdf